FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to immunology, cell biotechnologies, and can be used for recovery of anti-tumour immunity and tumour growth inhibition with further application in the clinical practice. Disclosed is a method of tumour growth inhibition based on in vitro reprogramming macrophages on M1 phenotype with high ability of nitric oxide production in experiment, when cultivating macrophages in the serum-free medium, wherein the IFN-γ 20 ng/ml is being added to the serum-free medium.
EFFECT: technical result is producing the M1 macrophage phenotype with effective anti-tumour mechanisms, characterized by high NO production, that provides higher stability of formed phenotype to reprogramming tumour effect.
1 cl, 3 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TUMOUR GROWTH INHIBITION IN EXPERIMENT | 2015 |
|
RU2599438C1 |
| METHOD OF SELECTING MEDICINAL PRODUCTS FOR PHARMACOLOGICAL INDUCTION OF MITOCHONDRIAL DYSFUNCTION IN MACROPHAGES FOR ANTITUMOR THERAPY | 2023 |
|
RU2810558C1 |
| METHOD OF SUPPRESSION OF INFLAMMATORY RESPONSE IN PERIODONTAL TISSUES IN AN EXPERIMENT | 2017 |
|
RU2677642C1 |
| METHOD FOR IDENTIFYING FUNCTIONAL M1 AND M2 PHENOTYPE OF HUMAN MACROPHAGES GENERATED IN VITRO FROM BLOOD MONOCYTES | 2019 |
|
RU2717024C1 |
| METHOD FOR OBTAINING PRIMARY MACROPHAGE LINES WITH PRO-INFLAMMATORY PROPERTIES | 2022 |
|
RU2792602C1 |
| METHOD FOR ENHANCING ANTITUMOR T-CELL IMMUNITY IN LUNG CANCER PATIENTS | 2022 |
|
RU2793914C1 |
| USE OF GRAPHENE OXIDE TO ACTIVATE PHAGOCYTIC FUNCTION OF MACROPHAGES | 2022 |
|
RU2809372C1 |
| MONONECLEAR DINITROSYL FERRIC COMPLEXES, METHOD FOR PREPARING MONONECLEAR DINITROSYL FERRIC COMPLEXES, NITROGEN MONOXIDE DONOR, USING MONONECLEAR DINITROSYL FERRIC COMPLEXES AS ANTI-TUMOUR DRUG | 2011 |
|
RU2494104C2 |
| AGENT HAVING IMMUNOMODULATORY ACTIVITY | 2019 |
|
RU2734420C1 |
| COMBINED CELL TRANSPLANT BASED ON LYMPHOKINE-ACTIVATED KILLERS AND DENDRITE CELLS, METHOD FOR PRODUCTION THEREOF AND METHOD FOR TREATMENT AND PROPHYLAXIS OF MALIGNANT, INFECTIVE DISEASES AND IMMUNODEFICIENT CONDITIONS | 2006 |
|
RU2309753C1 |
